Shares of GeneDx Holdings fell after the rare-disease-diagnosis company tempered its full-year outlook and widened its third-quarter loss.
The stock fell 16%, to $55.26, in midday trading Tuesday. Shares are down 58% year to date.
GeneDx late Monday said it widened its quarterly loss to $12.3 million, or 41 cents a share, from a loss of $7.64 million, or 27 cents a share, a year earlier.
Stripping out one-time items, the company reported quarterly earnings of 28 cents a share. Analysts polled by FactSet expected adjusted earnings of 7 cents a share.
Total revenue climbed 5.5% to $123.1 million, ahead of Wall Street models for $122.9 million.
Exome and genome test revenue increased 12% from last year, to $110.4 million, while test-result volume increased 25%, to 32,134.
Looking ahead, GeneDx maintained its outlook for full-year revenue of $475 million to $490 million, compared with analyst views for $477.7 million. However, its fourth-quarter revenue expectation of $135 million missed Wall Street estimates for $142.6 million.
The company also tempered its 2026 guidance for its exome and genome test business. It now expects full-year revenue growth in the segment of at least 17%, down from a prior outlook for at least 20% growth, as well as test-result volume growth of at least 28%, down from a previous forecast for at least 30% growth.
Comments